Peritoneal Cancer Clinical Trials 2023

What are the top hospitals conducting peritoneal cancer research?

When it comes to cutting-edge clinical trials in the field of peritoneal cancer, several hospitals across the United States are leading the way. In Houston, M D Anderson Cancer Center has emerged as a frontrunner with an impressive 12 active peritoneal cancer trials and a total of 24 trials conducted thus far. This esteemed institution began its pioneering journey in this domain in 2005. Meanwhile, nestled in Aurora, Colorado, the University of Colorado Hospital is making significant strides with ten ongoing peritoneal cancer trials and eight completed studies since initiating their first trial also in 2005.

Roswell Park Cancer Institute located in Buffalo is another notable player with nine active clinical trials focused on peritoneal cancer; they have previously conducted seventeen investigations dating back to their very first trial recorded all the way back in 1992. UC San Diego Moores Cancer Center situated in La Jolla maintains a strong commitment to combatting this disease as well, currently undertaking seven active peritoneal cancer trials while having achieved seven previous ones since recording their inaugural trial alongside others from hospitals during that same year -2005.

Last but not least, Cedars Sinai Medical Center situated within Los Angeles demonstrates dedication by contributing valuable insights through their involvement in seven ongoing peritoneal cancer trials and four accomplished studies so far. It's noteworthy how although Cedars Sinai Medical Centre appears smaller-scale when compared to other renowned institutions mentioned earlier; its contributions should not be underestimated given that they have been able to make substantial progress despite conducting fewer overall studies from starting out during same crucial timeline-2005.

These top medical centers symbolize hope for those affected by peritoneal cancers by actively exploring new frontiers through clinical research programs worldwide teaming up together illuminating paths towards better understanding combating such ailments assuring brighter future countless patients globally who suffer these conditions.

Which are the best cities for peritoneal cancer clinical trials?

When it comes to peritoneal cancer clinical trials, several cities stand out as hubs of research and innovation. Denver, Colorado leads the way with 29 active trials focused on areas such as Quality-of-Life Assessment, Paclitaxel, and Pharmacological Study. Sacramento, California closely follows with 29 ongoing studies exploring treatments like Paclitaxel and Bevacizumab. Chicago, Illinois is another key city in this field with 28 active trials investigating Paclitaxel, Pharmacological Study, and Quality-of-Life Assessment. Anchorage in Alaska also shows promise with 27 active trials examining Letrozole, Bevacizumab, and Quality-of-Life Assessment. Los Angeles rounds up the list with 26 ongoing trials studying Paclitaxel and exploring aspects of Quality-of-Life Assessment among other approaches. These cities provide individuals fighting peritoneal cancer access to cutting-edge clinical trials that hold potential for improved outcomes and better quality of life.

Which are the top treatments for peritoneal cancer being explored in clinical trials?

Clinical trials for peritoneal cancer have identified several top treatments that show promise in fighting this challenging disease. Paclitaxel, a drug first listed in 2002, is leading the pack with nine active trials and an impressive track record of 40 all-time peritoneal cancer trials. Additionally, pharmacological studies are being conducted in four ongoing trials to explore new avenues of treatment. Quality-of-life assessments also play a crucial role, with four active trials dedicated to understanding the impact of various interventions on patients' well-being. Lastly, olaparib stands out as a potential game-changer, currently being tested in three active clinical trials for peritoneal cancer since its introduction in 2016. As researchers delve deeper into these innovative approaches, hope shines brighter for individuals battling this complex form of cancer.

What are the most recent clinical trials for peritoneal cancer?

Exciting developments in clinical trials offer hope for individuals diagnosed with peritoneal cancer. The mEPIC trial, a Phase 2 study, presents an opportunity to explore innovative approaches in the treatment of this disease. Additionally, the IP FT538 + Enoblituzumab trial investigates the potential benefits of combining different therapies for peritoneal cancer patients. Another promising avenue is examined through the Pembrolizumab and Vismodegib trials, both in Phase 2, which aim to assess the effectiveness of these drugs against peritoneal cancer. Finally, a combination therapy involving Chemotherapy + BEV + IMNN-001 shows promise as it progresses through Phases 1 and 2 of its clinical trial journey. These recent studies mark significant strides towards improving outcomes and enhancing treatment options for those affected by peritoneal cancer.

What peritoneal cancer clinical trials were recently completed?

Several noteworthy clinical trials investigating treatments for peritoneal cancer have achieved significant milestones, bringing hope to patients battling this challenging disease. One recent completion in November 2021 was the trial sponsored by OncoNano Medicine, Inc., which explored the potential of pegsitacianine therapy. Furthermore, a study led by Dan Blazer III, M.D., concluded in May 2019 and focused on Talimogene Laherparepvec's effectiveness against peritoneal cancer. Other notable completed trials include Atezolizumab (March 2017) sponsored by Hoffmann-La Roche, Rucaparib (March 2017) sponsored by Clovis Oncology, Inc., Hyperthermic Intraperitoneal Chemotherapy (September 2016) conducted at M.D. Anderson Cancer Center and Oxaliplatin (July 2016) spearheaded by the University of Massachusetts Worcester. These advancements highlight ongoing efforts to improve outcomes for individuals affected by peritoneal cancer.